Miglustat is a Small Molecule owned by Johnson & Johnson, and is involved in 10 clinical trials, which were completed.
Miglustat is an N-alkylated imino sugar, a synthetic analog of D-glucose. It function as a competitive and reversible inhibitor of the enzyme glucosylceramide synthase, the initial enzyme in a series of reactions which results in the synthesis of most glycosphingolipids. It reduces the rate of glycosphingolipid biosynthesis so that the amount of glycosphingolipid substrate is reduced to a level which allows the residual activity of the deficient glucocerebrosidase enzyme to be more effective (substrate reduction therapy).
The revenue for Miglustat is expected to reach a total of $2.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Miglustat NPV Report.
Miglustat (Zavesca) is a glucosylceramide synthase inhibitor class of drug. It is formulated as hard gelatin capsule for oral route of administration. It is indicated for the treatment of mild to moderate type 1 Gaucher disease in patients who cannot be treated with enzyme replacement therapy. It is also approved to slow the progression of neurological manifestations in adult and pediatric patients with Niemann-Pick Type C disease.
Miglustat is under development for the treatment of Gaucher's disease type III. It was under development for the treatment of Niemann-Pick type C (NP-C) disease, acute infantile onset GM2 gangliosidosis, Fabry disease and cystic fibrosis.
Johnson & Johnson Overview
Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; consumer products in oral care, baby care, beauty, over-the-counter (OTC) medicines, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopaedic, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.
The company reported revenues of (US Dollars) US$93,775 million for the fiscal year ended January 2021 (FY2021), an increase of 13.6% over FY2020. In FY2021, the company’s operating margin was 24.3%, compared to an operating margin of 20% in FY2020. In FY2021, the company recorded a net margin of 22.3%, compared to a net margin of 17.8% in FY2020. The company reported revenues of US$23,791 million for the third quarter ended October 2022, a decrease of 1% over the previous quarter.
Quick View – Miglustat
|Highest Development Stage|